For example, using ipilimumab (anti-CTLA-4 monoclonal antibody) and nivolumab (anti-PD-1 monoclonal antibody) together increases the risk of myocarditis by 4.74 times when compared to using nivolumab just by itself (153). This evidence concerns the gene CTLA4 and myocarditis.